Location: Online, Virtual
Date: September 17 to September 21
Spotlight on the emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC)
Prof. Peter Galle speaks about the emerging therapies on advanced RCC, HCC and DTC.
The MONALEESA-2 trial
Prof. Gabriel N. Hortobagyi speaks about the overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative advanced breast cancer treated with endocrine therapy ± ribociclib.
Should Cure Be A Reasonable Goal in aRCC?
Prof. David F. McDermott speaks about the long-term survival of patients with kidney cancer.
Is Unresectable Malignant Pleural Mesothelioma a New Frontier for I-O?
Prof. Alessandra Curioni speaks about the update of CheckMate 743 trial.
The Keynote 716 trial
Prof. Jason J. Luke speaks about the efficacy and safety results from the Keynote 716 double-blinded phase III trial. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma.
Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB
Prof. Judy King speaks about the treatment of HER2+ Metastatic Breast Cancer.
Metastases-free survival results from STAMPEDE trial
Highlights of the ESMO 2021 Congress
Prof. Solange Peters speaks about the most important presentations on ESMO 2021.